Boothbay Fund Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Boothbay Fund Management’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-50,000	Closed	-$380K	–	1973
2025 Q3	$380K	Sell	50,000 -224,127	-82%	-$1.87M	0.01%	1320
2025 Q2	$2.46M	Sell	274,127 -1,050,094	-79%	-$9.78M	0.05%	459
2025 Q1	$9.93M	Sell	1,324,221 -60,412	-4%	-$487K	0.26%	75
2024 Q4	$10.4M	Buy	1,384,633 +190,574	+16%	+$1.45M	0.26%	92
2024 Q3	$9.07M	Sell	1,194,059 -941,204	-44%	-$7.15M	0.21%	111
2024 Q2	$13.2M	Buy	2,135,263 +1,672,929	+362%	+$9.23M	0.31%	43
2024 Q1	$2.35M	Buy	+462,334	New	+$2.6M	0.05%	447
2020 Q1	–	Sell	-30,000	Closed	-$104K	–	856
2019 Q4	$104K	Buy	+30,000	New	+$75.5K	0.01%	754
2018 Q4	–	Sell	-73,065	Closed	-$557K	–	669
2018 Q3	$557K	Buy	73,065 +59,065	+422%	+$397K	0.06%	330
2018 Q2	$80K	Buy	+14,000	New	+$77.1K	0.01%	695

Other funds holding BCRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Boothbay Fund Management's BCRX Position: Q4 2025 in Review

Boothbay Fund Management sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2025, closing a stake of 50,000 shares — an estimated $380K sold.

Boothbay Fund Management first reported a position in BCRX in Q2 2018 and held it in 10 quarters. The position peaked at $13.2M in Q2 2024. 273 funds tracked by Wall St. Rank hold BCRX as of Q4 2025.

Boothbay Fund Management reported no remaining BioCryst Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Boothbay Fund Management sold 50,000 BioCryst Pharmaceuticals shares in Q4 2025, an estimated $380K.
Boothbay Fund Management first reported a position in BioCryst Pharmaceuticals in Q2 2018 and held it in 10 quarters.
Boothbay Fund Management's BioCryst Pharmaceuticals position peaked at $13.2M in Q2 2024.
273 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2025.

Based on Boothbay Fund Management's 13F filing for Q4 2025, filed 17 Feb 2026.